RECBIO-B has reached a product authorization cooperation with India's Biological E for the restructured nine-valent HPV vaccine REC603
I'm PortAI, I can summarize articles.
RECBIO-B has signed a product licensing cooperation agreement for the recombinant nine-valent HPV vaccine REC603 with India's Biological E. According to the agreement, Biological E will be exclusively responsible for the development, production, and commercialization of the vaccine in India and markets led by UNICEF and PAHO. RECBIO will provide licensing for the vaccine formulation and packaging technology, and will grant licensing for the bulk production technology at an appropriate time. The company has received an advance payment for the cooperation and will receive milestone payments and royalties based on progress
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments